Item S1. Sensitivity Analyses

Association of Serum Bica	arbonate with Lumbar and '	Total Bone Mineral Dens	ity
		Coefficient (95% CI)	
	Total Population	Men	Women
Lumbar BMD (g/cm ²)			
Continuous*	0.006 (0.001,0.010)	0.008 (0.002,0.015)	0.008 (0.001,0.014)
< 24 mEq/L	[Ref]	[Ref]	[Ref]
24 – 25 mEq/L	0.004 (-0.006,0.014)	-0.005 (-0.024,0.013)	0.016 (0.003,0.028)
25.1 – 26.9 mEq/L	0.010 (-0.001,0.020)	0.010 (-0.006,0.026)	0.018 (0.004,0.031)
\geq 27 mEq/L	0.016 (0.004,0.028)	0.020 (0.002,0.038)	0.022 (0.005,0.039)
P for trend	0.007	0.01	0.008
Total BMD (g/cm ²)			
Continuous*	0.003 (-0.0001, 0.007)	0.004 (-0.0004,0.009)	0.006 (0.001,0.010)
< 24 mEq/L	[Ref]	[Ref]	[Ref]
24 – 25 mEq/L	0.006 (-0.003,0.016)	0.005 (-0.010,0.020)	0.009 (-0.0003,0.019)
25.1 - 26.9 mEq/L	0.003 (-0.006,0.012)	0.005 (-0.008,0.018)	0.006 (-0.002,0.014)
\geq 27 mEq/L	0.011 (-0.001,0.023)	0.012 (-0.002,0.027)	0.019 (0.005,0.033)
P for trend	0.1	0.1	0.01

Table a. Sensitivity Analysis After Adjusting for Loop Diuretic Use

Abbreviations: eGFR, estimate glomerular filtration rate; BMD, bone mineral density; CI,

confidence interval. **Bold** values indicate p<0.05.

Models adjusted for age, sex, race/ethnicity, body mass index, poverty, education, activity level, smoking status, fasting length, loop diuretic and calcium carbonate use, diagnosis of diabetes mellitus, hypertension and cardiovascular disease, eGFR, albuminuria, serum albumin, calcium, phosphate and C-reactive protein.

Association of Serum Bica	rbonate with Lumbar and	Total Bone Mineral Dens	ity
		Coefficient (95% CI)	
	Total Population	Men	Women
Lumbar BMD (g/cm ²)			
Continuous*	0.005 (0.001,0.010)	0.009 (0.002,0.015)	0.007 (0.001,0.014)
< 24 mEq/L	[Ref]	[Ref]	[Ref]
24 – 25 mEq/L	0.004 (-0.006,0.014)	-0.006 (-0.024,0.013)	0.016 (0.003,0.028)
25.1 – 26.9 mEq/L	0.009 (-0.001,0.020)	0.010 (-0.006,0.026)	0.017 (0.004,0.031)
$\geq 27 \text{ mEq/L}$	0.015 (0.003,0.028)	0.020 (0.002,0.038)	0.021 (0.005,0.038)
P for trend	0.01	0.01	0.01
Total BMD (g/cm ²)			
Continuous*	0.003 (-0.001,0.007)	0.004 (-0.001,0.009)	0.005 (0.001,0.010)
< 24 mEq/L	[Ref]	[Ref]	[Ref]
24 – 25 mEq/L	0.006 (-0.003,0.016)	0.005 (-0.010,0.020)	0.009 (-0.0003,0.019)
25.1 – 26.9 mEq/L	0.003 (-0.006,0.012)	0.005 (-0.008,0.018)	0.006 (-0.002,0.014)
\geq 27 mEq/L	0.011 (-0.001,0.023)	0.012 (-0.003,0.027)	0.019 (0.004,0.033)
P for trend	0.1	0.1	0.02

Table b. Sensitivity Analysis After Adjusting for Thiazide Diuretic U	se

Abbreviations: eGFR, estimate glomerular filtration rate; BMD, bone mineral density; CI, confidence interval. **Bold** values indicate p<0.05.

Models adjusted for age, sex, race/ethnicity, body mass index, poverty, education, activity level, smoking status, fasting length, thiazide diuretic and calcium carbonate use, diagnosis of diabetes mellitus, hypertension and cardiovascular disease, eGFR, albuminuria, serum albumin, calcium, phosphate and C-reactive protein.

-

		Coefficient (95% CI)	
	Total Population	Men	Women
Lumbar BMD (g/cm ²)			
Continuous*	0.005 (0.001,0.010)	0.008 (0.002,0.015)	0.007 (0.001,0.014)
< 24 mEq/L	[Ref]	[Ref]	[Ref]
24 – 25 mEq/L	0.004 (-0.007,0.014)	-0.005 (-0.024,0.013)	0.016 (0.003,0.028)
25.1 - 26.9 mEq/L	0.009 (-0.001,0.020)	0.010 (-0.005,0.026)	0.017 (0.004,0.031)
\geq 27 mEq/L	0.015 (0.003,0.028)	0.019 (0.001,0.037)	0.021 (0.004,0.038)
P for trend	0.01	0.01	0.01
Total BMD (g/cm ²)			
Continuous*	0.003 (-0.001,0.007)	0.004 (-0.0005,0.009)	0.005 (0.001,0.010)
< 24 mEq/L	[Ref]	[Ref]	[Ref]
24 – 25 mEq/L	0.006 (-0.003,0.016)	0.005 (-0.010,0.020)	0.009 (-0.0003,0.019)
25.1 - 26.9 mEq/L	0.003 (-0.006,0.012)	0.005 (-0.008,0.018)	0.006 (-0.002,0.014)
\geq 27 mEq/L	0.011 (-0.001,0.024)	0.013 (-0.002,0.027)	0.019 (0.005,0.033)
P for trend	0.1	0.09	0.01

Tal	ole <i>c</i> . Se	nsitivity	Analys	sis A	fter	Adjustii	ng foi	r Loop and Thi	azide D	oiuretic	Use	
												_

Abbreviations: eGFR, estimate glomerular filtration rate; BMD, bone mineral density; CI, confidence interval. **Bold** values indicate p<0.05.

Models adjusted for age, sex, race/ethnicity, body mass index, poverty, education, activity level, smoking status, fasting length, loop and thiazide diuretic and calcium carbonate use, diagnosis of diabetes mellitus, hypertension and cardiovascular disease, eGFR, albuminuria, serum albumin, calcium, phosphate and C-reactive protein.

Association of Serum Bica	arbonate with Lumbar and	Total Bone Mineral Dens	ity
		Coefficient (95% CI)	
	Total Population	Men	Women
Lumbar BMD (g/cm ²)			
Continuous*	0.005 (-0.0003,0.010)	0.006 (-0.001,0.014)	0.007 (-0.0003,0.015)
< 24 mEq/L	[Ref]	[Ref]	[Ref]
24 – 25 mEq/L	0.002 (-0.010,0.014)	-0.012 (-0.033,0.009)	0.018 (0.004,0.031)
25.1 - 26.9 mEq/L	0.007 (-0.005,0.019)	0.002 (-0.019,0.022)	0.018 (0.003,0.033)
\geq 27 mEq/L	0.013 (-0.0006,0.026)	0.012 (-0.009,0.034)	0.021 (0.001,0.041)
P for trend	0.06	0.1	0.03
Total BMD (g/cm ²)			
Continuous*	0.005 (0.0001,0.009)	0.005 (-0.001,0.010)	0.008 (0.002,0.013)
< 24 mEq/L	[Ref]	[Ref]	[Ref]
24 – 25 mEq/L	0.003 (-0.009,0.015)	-0.003 (-0.021,0.016)	0.010 (-0.002,0.023)
25.1 - 26.9 mEq/L	0.004 (-0.007,0.015)	0.001 (-0.016,0.017)	0.012 (0.004,0.021)
\geq 27 mEq/L	0.014 (0.001,0.028)	0.011 (-0.006,0.028)	0.025 (0.010,0.041)
P for trend	0.05	0.2	0.001

_	Table d. Sensitivity Analysis After Adjustment for 25-Hydroxy Vitamin D Level (n=6,963)
_	Association of Sarum Bicarbonate with Lumbar and Total Bone Mineral Density

Abbreviations: BMD, bone mineral density; CI, confidence interval. **Bold** values indicate p<0.05.

Models adjusted for age, sex, race/ethnicity, body mass index, poverty, education, activity level, smoking status, fasting length, diuretic and calcium carbonate use, diagnosis of diabetes mellitus, hypertension and cardiovascular disease, eGFR, albuminuria, serum albumin, calcium,

phosphate, serum 25-hydroxy vitamin D level (2001-2004), C-reactive protein.

-

		Coefficient (95% CI)	
	Total Population	Men	Women
Lumbar BMD (g/cm ²)			
Continuous*	0.005 (-0.0001,0.010)	0.006 (-0.001,0.014)	0.008 (0.0001,0.016)
< 24 mEq/L	[Ref]	[Ref]	[Ref]
24 – 25 mEq/L	0.003 (-0.009,0.015)	-0.011 (-0.032,0.010)	0.018 (0.005,0.032)
25.1 – 26.9 mEq/L	0.007 (-0.006,0.019)	0.002 (-0.019,0.023)	0.018 (0.003,0.034)
$\geq 27 \text{ mEq/L}$	0.013 (0.0001,0.027)	0.012 (-0.009,0.034)	0.023 (0.002,0.043)
P for trend	0.05	0.1	0.02
Fotal BMD (g/cm ²)			
Continuous*	0.005 (0.0002,0.010)	0.005 (-0.0005,0.010)	0.008 (0.002,0.013)
< 24 mEq/L	[Ref]	[Ref]	[Ref]
24 – 25 mEq/L	0.004 (-0.008,0.016)	-0.001 (-0.020,0.017)	0.010 (-0.001,0.022)
25.1 – 26.9 mEq/L	0.004 (-0.007,0.016)	0.001 (-0.016,0.018)	0.012 (0.003,0.021)
\geq 27 mEq/L	0.015 (0.001,0.029)	0.012 (-0.006,0.029)	0.026 (0.011,0.042)
P for trend	0.05	0.2	0.001

Tab	ole e. Sei	nsitivity	Analysis	S After	[.] Adjust	ment for	Vitamin	D Suppler	nentati	on (n=7,0	JO2)
						-			1.5		

Abbreviations: BMD, bone mineral density; CI, confidence interval. **Bold** values indicate p<0.05.

Models adjusted for age, sex, race/ethnicity, body mass index, poverty, education, activity level, smoking status, fasting length, diuretic and calcium carbonate use, diagnosis of diabetes mellitus, hypertension and cardiovascular disease, eGFR, albuminuria, serum albumin, calcium,

phosphate, vitamin D supplementation (2001-2004), C-reactive protein.

		Coefficient (95% CI)	
	Total Population	Men	Women
umbar BMD (g/cm ²)			
Continuous*	0.007 (0.001,0.013)	0.008 (-0.0004,0.016)	0.010 (0.003,0.018)
< 23 mEq/L	[Ref]	[Ref]	[Ref]
23 – 24 mEq/L	0.008 (-0.003,0.018)	0.009 (-0.007,0.026)	0.012 (-0.002,0.026)
25.1 – 25.9 mEq/L	0.015 (0.002,0.029)	0.022 (0.002,0.042)	0.021 (-0.003,0.045)
$\geq 26 \text{ mEq/L}$	0.019 (0.003,0.035)	0.022 (-0.003,0.046)	0.027 (0.007,0.047)
P for trend	0.02	0.06	0.01
Total BMD (g/cm ²)			
Continuous*	0.004 (-0.001,0.008)	0.004 (-0.002,0.010)	0.006 (0.001,0.011)
< 23 mEq/L	[Ref]	[Ref]	[Ref]
23 – 24 mEq/L	0.006 (-0.001,0.014)	0.013 (0.001,0.025)	0.003 (-0.006,0.012)
25.1 – 25.9 mEq/L	0.008 (-0.003,0.020)	0.012 (-0.003,0.026)	0.013 (-0.001,0.028)
$\geq 26 \text{ mEq/L}$	0.012 (-0.002,0.025)	0.014 (-0.002,0.031)	0.018 (0.001,0.035)
P for trend	0.09	0.1	0.02

Table f. Sensitivity Analysis using Serum Bicarbonate without Correction Factor (1999-2002)
A mention of Community and an external transformer of Tetal Development Development

Abbreviations: BMD, bone mineral density; CI, confidence interval. **Bold** values indicate p<0.05.

Models adjusted for age, sex, race/ethnicity, body mass index, poverty, education, activity level, smoking status, fasting length, diuretic and calcium carbonate use, diagnosis of diabetes mellitus, hypertension and cardiovascular disease, eGFR, albuminuria, serum albumin, calcium, phosphate, C-reactive protein.

	OR (95	% CI)
	Men	Women
Low Lumbar Bone Mass		
Continuous*	0.90 (0.78,1.04)	0.91 (0.79,1.04)
< 24 mEq/L	[Ref]	[Ref]
24 – 25 mEq/L	1.09 (0.54,2.21)	0.94 (0.66,1.32)
25.1 – 26.9 mEq/L	1.14 (0.67,1.93)	1.01 (0.73,1.41)
$\geq 27 \text{ mEq/L}$	0.73 (0.44,1.22)	0.74 (0.52,1.06)
P for trend	0.2	0.2
Low Total Bone Mass		
Continuous*	0.96 (0.83,1.12)	0.90 (0.77,1.05)
< 24 mEq/L	[Ref]	[Ref]
24 – 25 mEq/L	0.71 (0.49,1.04)	0.96 (0.61,1.53)
25.1 – 26.9 mEq/L	0.80 (0.55,1.18)	0.95 (0.57,1.58)
$\geq 27 \text{ mEq/L}$	0.82 (0.53,1.25)	0.65 (0.43,0.99)
P for trend	0.5	0.08

Table g. Sen	sitivitv A	nalvsis of]	Logistic	Regression	for Participants	>50 Years	Old (n=2.072)
							()-)

Abbreviations: OR, odds ratio; CI, confidence interval. **Bold** values indicate p<0.05.

Models adjusted for age, race/ethnicity, body mass index, poverty, education, activity level, smoking status, fasting length, diuretic and calcium carbonate use, diagnosis of diabetes mellitus, hypertension and cardiovascular disease, eGFR, albuminuria, serum albumin, calcium, phosphate and C-reactive protein.